The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
Open accessAbstract
BACKGROUND: Microalbuminuria is an early predictor of diabetic nephropathy and premature cardiovascular disease. We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. METHODS: In a randomized, double-blind, multicenter, controlled trial, we assigned 4447 patients with type 2 diabetes to receive olmesartan (at a dose of 40 mg once daily) or placebo for a median of 3.2 years. Additional antihypertensive drugs (except angiotensin-converting-enzyme inhibitors or ARBs) were used as needed to lower blood pressure to less than 130/80 mm Hg. The primary outcome was the time to the first onset of microalbuminuria. The times to the onset of renal and cardiovascular events were analyzed as secondary end points. RESULTS: The target blood pressure (<130/80 mm Hg) was achieved in nearly 80% of the patients taking olmesartan and 71% taking placebo; blood pressure measured in the clinic was lower by 3.1/1.9 mm Hg in the olmesartan group than in the placebo group. Microalbuminuria developed in 8.2% of the patients in the olmesartan group (178 of 2160 patients who could be evaluated) and 9.8% in the placebo group (210 of 2139); the time to the onset of microalbuminuria was increased by 23% with olmesartan (hazard ratio for onset of microalbuminuria, 0.77; 95% confidence interval, 0.63 to 0.94; P=0.01). The serum creatinine level doubled in 1% of the patients in each group. Slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events--81 of 2232 patients (3.6%) as compared with 91 of 2215 patients (4.1%) (P=0.37)--but a greater number had fatal cardiovascular events--15 patients (0.7%) as compared with 3 patients (0.1%) (P=0.01), a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease (11 of 564 patients [2.0%] vs. 1 of 540 [0.2%], P=0.02). CONCLUSIONS: Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards. The higher rate of fatal cardiovascular events with olmesartan among patients with preexisting coronary heart disease is of concern. (Funded by Daiichi Sankyo; ClinicalTrials.gov number, NCT00185159.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a trial of people with type 2 diabetes and normal urinary albumin excretion, an ARB reduced or suppressed the development of albuminuria but increased the rate of cardiovascular events (86).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“but cardiovascular events were increased. 59”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Available data suggest that ACEi and ARB treatments are not bene fi cial for patients with neither albuminuria nor elevated blood pressure.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In T2D with neither albuminuria nor elevated blood pressure (normal or well-treated), moderately increased albuminuria was observed less frequently with an ARB”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a trial of people with type 2 diabetes and normal urinary albumin excretion, an ARB reduced or suppressed the development of albuminuria but increased the rate of cardiovascular events (94).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [94]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citation2007 Guidelines for the Management of Arterial Hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,870
Self-citationMancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
MICROALBUMINURIA AS A PREDICTOR OF CLINICAL NEPHROPATHY IN INSULIN-DEPENDENT DIABETES MELLITUS
Viberti, G. C., Jarrett, R. J., Mahmud, U., Hill, R. D., Argyropoulos, A. N., & KEEN, H. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92450-3 · Cited by 1,662
Self-citationMancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328333146d · Cited by 1,643
Self-citationLindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–793 of 793
Nanosciences, Diabetes and the Patient
Martín, R. G. D. M., Le Mignon, L., Hunter, R. P., Patel, B., & Preedy, R. (2012) · Science Publishers eBooks · doi:10.1201/b11775-25
Off-target effects of RAAS-inhibition
Yan, M. (2012)
Clinical Case 3: Patient with Diabetes Mellitus
Virdis, A. (2016) · Practical case studies in hypertension management · doi:10.1007/978-3-319-39164-9_3
Wassermann, A. O., & Migueles, R. A. (2012) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/rev.hosp.ital.b.aires.v32i4.895
Hypertension: An Evidence Informed, Case Based Approach
Mackie, A. S. (2017) · Physician Assistant Clinics · doi:10.1016/j.cpha.2017.06.001
Effect of antihypertensive treatment at different blood pressure levels
Brunström, M. (2017) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Евдокимова, А. Г., Ryzhova, Y. V., & Gukolenko, L. V. (2016) · Journal of clinical practice · doi:10.17816/clinpract7111-21
Chronic Kidney Disease аs a Common Medical Problem
Alieva, T., & Ismayilova, G. E. (2018) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs03.02.185
FREQUENCY OF MICROALBUMINURIA IN PATIENTS WITH DIABETIC RETINOPATHY
Ali, M., Rehman, Y. F. U., & Tariq, H. (2018) · Journals & Books Hosting (International Knowledge Sharing Platform)
TAVR and DAPT: Are We Any Closer to the Answer?
Yakubov, S. J., Arshi, A., & Sanchez, C. E. (2018) · Structural Heart · doi:10.1080/24748706.2018.1495347
Хіміон, Л. В., Тимощук, Л. С., & Рибицька, М. О. (2018) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/1812-2892-jcmk-00560
Fuchs, S. C. P. C., & Fuchs, F. D. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-75310-2_36
Prehypertension: A Case in Favor of Early Use of Diuretics
Fuchs, F. D., & Fuchs, S. C. P. C. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-75310-2_40
The Heart Team Approach: What is the Role of the Surgeon?
Al‐Azizi, K., & Krueger, A. R. (2019) · Structural Heart · doi:10.1080/24748706.2019.1670885
Angioprotection role in arterial hypertension treatment: focus on olmesartan
Небиеридзе, Д. В., Safaryan, A. S., Ivanishina, T. V., & Vinnitskaya, N. L. (2012) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2012-5-67-70
Diabetic kidney disease: a case for precision medicine?
Currie, G. E., Mullen, B., & Delles, C. (2016) · The Biochemist · doi:10.1042/bio03801022
Chatzikyrkou, C., Scurt, F. G., Menne, J., Korda, A. I., Mertens, P. R., & Haller, H. G. (2020) · Blood Pressure · doi:10.1080/08037051.2020.1750298
Self-citationElliott, W. J., & Black, H. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2766-1.00021-1
Renovaskuläre Effekte von SGLT-2-Inhibitoren
Hohenstein, B., & Hugo, C. (2020) · Diabetes aktuell · doi:10.1055/a-1152-2146
Scurt, F. G., Menne, J., Korda, A. I., Haller, H. G., & Chatzikyrkou, C. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13102
Self-citationEbzeeva, E. Y., Ostroumova, O. D., Doldo, N. M., & Евгеньевна, П. Е. (2020) · Medical alphabet · doi:10.33667/2078-5631-2020-21-19-28
The optimization of the drug therapy in patients with resistant hypertension (clinical analysis)
Rodionov, A. V. (2013) · Cardiosomatics · doi:10.26442/cs45022
Teplova, N. V., Михайлович, Е. Е., Artamonova, N. G., Chervyakova, G. А., & Dzheksembekov, A. G. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-4-12-16
Gliflozins slow down the progression of diabetic kidney disease
Tesař, V., & Vachek, J. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.143
심혈관 질환에서 안지오텐신 II 수용체 차단제의 최근 논점들
윤현주, & 김계훈 (2012)
Ai, S., Han, Y., Gao, Y., Wang, Y., Zhou, J., Liu, W., Han, X., Chen, Z., Liu, Q., Chen, W., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-464664/v1
片山, 茂., 野口, 雄., & 波多野雅子 (2014) · 糖尿病 · doi:10.11213/tonyobyo.57.501
Diabetes and Kidney Disease: A Review of the Clinical Practice Guidelines
Aggarwal, N., Ali, S., & Navaneethan, S. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_2
Prävention der diabetischen Nephropathie: Was ist praktisch machbar?
Rüster, C., & Wolf, G. (2015) · Deutsches Ärzteblatt · doi:10.3238/persdia.2015.04.24.01
Elliott, W. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_23
Metaanalyse: Assoziation antihypertensive Therapie – unerwünschte Ereignisse
(2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1401-8298
Anlauf, M., & Weber, F. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_17
Hemmstoffe des Renin-Angiotensin-Systems
Weber, F., & Anlauf, M. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_8
Hemmstoffe des Renin- Angiotensin-Systems
Anlauf, M., & Weber, F. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_5
Ott, C., & Schmieder, R. E. (2022) · Kidney International · doi:10.1016/j.kint.2022.01.026
Hemmstoffe des Renin-Angiotensin-Systems
Anlauf, M., & Weber, F. (2013) · Springer eBooks · doi:10.1007/978-3-642-37124-0_5
Hemmstoffe des Renin-Angiotensin-Systems
Anlauf, M. (2012) · Springer eBooks · doi:10.1007/978-3-642-29242-2_5
Anlauf, M., & Weber, F. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_17
García‐Prieto, A., Verdalles, Ú., & Goicoechea, M. (2021) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.12.023
Anlauf, M. (2013) · Springer eBooks · doi:10.1007/978-3-642-37124-0_14
Sämann, A., & Wolf, G. (2013) · Humanmedizin kompakt · doi:10.1007/s40355-012-0006-x
Anlauf, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_14
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch4
Weir, M. R. (2015) · Journal of Indian College of Cardiology · doi:10.1016/j.jicc.2015.03.021
Solini, A., & Castellino, P. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_8
Solini, A., & Castellino, P. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_8
Solini, A., & Castellino, P. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_8-1
Anlauf, M., & Weber, F. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_14
Anlauf, M. (2012) · Springer eBooks · doi:10.1007/978-3-642-29242-2_14
Beaussier, H., Laurent, S., & Boutouyrie, P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5198-2_40
Anlauf, M., & Weber, F. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_13
Significance of the nephroprotective effect of sartan in the treatment of hypertension
Stanković, I. (2022) · Galenika Medical Journal · doi:10.5937/galmed2202053s
Hemmstoffe des Renin-Angiotensin-Systems
Anlauf, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_5
Secondary Diseases of the Kidney
Natale, P., Wong, M. G., Strippoli, G. F., Tunnicliffe, D. J., Cooper, T. E., & Pollock, C. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch24
Blood Pressure-Lowering Treatment and Macrovascular Events
Thomopoulos, C. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_18
Effect of angiotensin receptor blocker dose in MI with preserved left ventricular systolic function
Kim, H.-Y., Mok, J., Kim, J., Jeon, D., Her, S., Park, M., Kim, D., Park, C.-S., Lee, J. M., Chang, K., et al. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001427
Sun, Y., Zhang, Z., Sun, W., Jin, D., An, X., Zhang, Y., Yang, C., Zhang, Y., Duan, Y., Kang, X., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4455400
Khedrimirghaed, M., Ghaneialvar, H., Mozafari, A., Heidari, M. A., & Bastaminejad, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3252557/v1
Albuminuria and cardiovascular risk
Rigo, D., Jimenez, P. M., & Orías, M. (2023) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2023.03.003 · Cited by 1
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00039-6
León, J. S. T., Ardila, L. J. P., Santamaria, M. J. C., Quintero, V. Q., Campo, E. R. Z., Corzo, M. J. O., Cantillo, F. A. A., Romero, L. D. J., Medina, R. A. A., Solano, M. J. C., et al. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i1.10179
Hypertonietherapie bei Nierenerkrankungen
Boger, L., & Saritas, T. (2024) · Nephrologie aktuell · doi:10.1055/a-2215-3675
Once in a Lifetime~Dream, Passion, Challenge, and Respect for Peers~
Ito, S. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej20231011
Self-citationУраження нирок при артеріальній гіпертензії (діагностичні й терапевтичні аспекти)
Koval, S. M., Рєзнік, Л. А., Старченко, Т. Г., & Литвинова, О. М. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.369 · Cited by 1
Kraft, L., & Latus, J. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21183-6.00003-9
Phrawong, S., Sorncha, N., Budkaew, J., & Chumworathayi, B. (2025) · Current Drug Therapy · doi:10.2174/0115748855377775250528115415
Metabolic syndrome: Pharmacological strategies and challenges
Heidari, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00014-7
Medications for the Management of Chronic Kidney Disease
Tran, E. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch25
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Are We Too Lenient Toward ARBs? A Balanced Appraisal in Light of New Multidatabase Evidence
Mourad, J., & Levy, B. I. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.26007
Maladie rénale chronique diabétique
Gosset, C., Rigalleau, V., Esnault, V. L. M., & Foussard, N. (2025) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)46692-4
Alsalemi, N., Sadowski, C. A., Elftouh, N., Louis, M., Kilpatrick, K., Houle, S. K. D., & Lafrance, J. (2022) · Figshare · doi:10.6084/m9.figshare.19681822
Alsalemi, N., Sadowski, C. A., Elftouh, N., Louis, M., Kilpatrick, K., Houle, S. K. D., & Lafrance, J. (2022) · Figshare · doi:10.6084/m9.figshare.19681828
Alsalemi, N., Sadowski, C. A., Elftouh, N., Louis, M., Kilpatrick, K., Houle, S. K. D., & Lafrance, J. (2022) · Figshare · doi:10.6084/m9.figshare.19681825
Muimba-Kankolongo, A., Nkulu, C. B. L., Mwitwa, J., Mujinga, F. K., & Nabuyanda, M. M. (2026) · Springer eBooks · doi:10.1007/978-3-031-96786-3_1
Saely, C. H., Schernthaner, G.-H., Brix, J. M., Klauser‐Braun, R., Zitt, E., Drexel, H., & Schernthaner, G. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02719-7
Bannuru, R. R., Fazioli, K., de Boer, I. H., Earley, A., ElSayed, N. A., Fioretto, P., Khunti, K., Navaneethan, S. D., Noble, M., Richardson, C., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0014
Antihypertensive Treatment in Chronic Kidney Disease: Current Algorithms
Theodorakopoulou, M. P., & Sarafidis, P. A. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_12
Lavie, C. J., & Banach, M. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag118
Primary Prevention of CKD for Heart and Kidney Health
Dorjee, T., Hawkins, N. M., Moghaddam, N., Elliott, M. D., & Levin, A. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001170
Hsu, W.-C., Hung, S., Lin, S.-H., Chiou, Y., Lin, Y., Wang, H.-H., Ho, L., & Lee, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2711459
Yu, Q., Ye, H., & Yan, H. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.07.014
Indian Guidelines on Hypertension (I.G.H.)-V. 2025–2026
Mehta, N., Mathur, G., Pal, J., Taneja, A., Wander, G. S., Pareek, K. K., Narsimulu, G., Saxena, P., Muruganathan, A., Chattetjee, N., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1495
Martínez‐Alberto, C. E., Bobadilla-Hernández, Z., & Donate‐Correa, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176913
Lindner, T. H. (2013) · Der Diabetologe · doi:10.1007/s11428-012-1015-x
Antihypertensive and Other Treatments in Early Stages of Diabetic Nephropathy
Elliott, W. J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0793-9_18
Metadata
- Authors
- Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., Rump, L. C., & Viberti, G.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Tohoku University (JP)
- Institute of Cardiology (PL)
- Saitama Medical University (JP)
- Hôpital Lapeyronie (FR)
- Leiden University Medical Center (NL)
- Heidelberg University (DE)
- Hospital Universitario 12 De Octubre (ES)
- Heinrich Heine University Düsseldorf (DE)
- Guy's Hospital (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-10
- Volume
- 364
- Issue
- 10
- Pages
- 907-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169506520
- Cited by
- 792
- References
- 30
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 19 · 2023: 26 · 2022: 39 · 2021: 36 · 2020: 39 · 2019: 34 · 2018: 58 · 2017: 51 · 2016: 59 · 2015: 67 · 2014: 66 · 2013: 74 · 2012: 115
- FWCI
- 80.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Amgen
- Pfizer
- Sanofi
- Bayer HealthCare
- Dainippon Sumitomo Pharma
- Astellas Pharma
- Shionogi
- Servier
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- olmesartan, microalbuminuria, type 2 diabetes, angiotensin receptor blockers, diabetic nephropathy, cardiovascular events, blood pressure control, renal protection, cardiovascular mortality, normoalbuminuria, serum creatinine doubling, antihypertensive therapy, renin-angiotensin system blockade, cardiovascular risk reduction
- MeSH terms
- Adolescent, Adult, Aged, Albuminuria, Blood Pressure, Cardiovascular Diseases, Coronary Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Imidazoles, Male, Middle Aged, Tetrazoles, Angiotensin II Type 1 Receptor Blockers, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
